SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
May 01, 2024 16:30 ET
|
Block & Leviton LLP
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Abeona Therapeutics, Inc. (NASDAQ: ABEO) for potential securities law violations. Investors who have lost money in their...
SHAREHOLDER ALERT: Abeona Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
April 23, 2024 10:29 ET
|
Block & Leviton LLP
BOSTON, April 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Abeona Therapeutics, Inc. (NASDAQ: ABEO) for potential securities law violations. Investors who have lost money in...
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
February 12, 2020 14:15 ET
|
Abeona Therapeutics Inc.
Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment Dose-dependent and sustained reductions in disease-specific biomarkers denotes clear biologic...
Abeona Therapeutics leitet klinische Phase-3-Schlüsselstudie zur Beurteilung der Gentherapie EB-101 bei rezessiver dystropher Epidermolysis bullosa (RDEB) ein
January 13, 2020 15:32 ET
|
Abeona Therapeutics Inc.
Die Studie ist für die Rekrutierung geöffnet und das Patientenscreening ist an der Stanford University angelaufen Das Unternehmen erwartet die Behandlung des ersten Patienten im ersten Quartal 2020 ...
Abeona Therapeutics lance un essai clinique pivot de phase 3 évaluant la thérapie génique EB-101 pour l'épidermolyse bulleuse dystrophique récessive
January 13, 2020 15:32 ET
|
Abeona Therapeutics Inc.
Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier patient soit traité au cours du premier trimestre...
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
January 13, 2020 09:00 ET
|
Abeona Therapeutics Inc.
Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in...
Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants
December 20, 2019 09:23 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its public...
Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
December 09, 2019 08:45 ET
|
Abeona Therapeutics Inc.
FDA removes clinical hold; Company may proceed with VIITAL™ study Company expects to initiate study in the first quarter of 2020 Primary endpoint confirmed as proportion of wounds with greater than...
Abeona Therapeutics Announces Strategic Review
September 03, 2019 09:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies...
Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
May 10, 2019 16:15 ET
|
Abeona Therapeutics Inc.
CMC work completed in advance of EB-101 Phase 3 VITAL™ trial expected to begin mid-2019 IND submitted for ABO-202 in CLN1 disease Investor conference call on Tuesday, May 14 at 10:00 a.m. ET NEW...